 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/224766
Cell Signalling Pathways - Productive Sources of Pharmaceutical Targets
|
Description: |
Cell signalling pathways are responsible for the normal function of all organ systems through controlling the interactions between and within cells. The cause of many diseases is the interruption of one or more of these pathways. Therefore, identifying key pathway components could be logical targets for the development of pharmaceuticals to treat these diseases.
Cell signalling pathways contain protein families that are targets for many highly successful drugs on the market today. Kinases, G-Protein Coupled Receptors (GPCRs), and nuclear receptors contained within cell signalling pathways have all been successfully modulated by drugs for the treatment of major disease, including cancer, diabetes, and inflammation. As the understanding of the molecular interactions within cell signalling pathways are more completely understood, new, highly specific drug targets will most likely be discovered, spurring the development of the next generation of targeted pharmaceuticals.
Scope
Our Cell Signalling Pathways Report provides an overview of major signalling pathways. A description of the individual components that have the potential to be exploited as drug targets are reviewed and drug candidates in development against many of these targets are analyzed. The Report also examines the successes and failures of drug development efforts thus far. In addition, 39 companies active in the cell signalling market are profiled in-depth.
Market Opportunities
- Develop new drugs that specifically target key components of cell signalling pathways in order to treat disease as effectively as current drugs on the market, but with reduced side effects.
- Build upon the success of current drugs targeting cell signalling pathways protein families through identifying the functions of those "orphan proteins" that are still unknown, which could lead to the development of new and effective therapies.
- Design and perform clinical trials that accurately reflect drug performance - preventing expensive, late-stage failures - through clearly understanding the limitations of cytostatic agents.
- Bring a biological drug to market quicker and cheaper through solid industry partnerships and a clear understanding of the roles of the FDA/CBER.
Key Reasons to Buy
- Get an in-depth look at cell signalling pathways via a concise overview of how they are implicated in significant human diseases, including cancer, inflammation & autoimmunity, and metabolic syndrome.
- Pinpoint the full market potential for cell signalling from a comprehensive assessment of the magnitude and impact of diseases caused by aberrant cell signalling and the deficiencies of currently marketed therapies.
- Identify the commercial opportunities for drugs directed toward abnormal cell signalling with a thorough review of specific pathway components that have the most potential as pharmaceutical targets.
- Obtain a complete and extensive appraisal of the development status of drug candidates currently in clinical development that target components of cell signalling pathways, including a discussion of reported clinical trial results.
- Look inside 39 companies active in cell signalling pathways, including their products and services, financial standing, key developments, alliances, and more.
|
|
Contents: |
1 Executive Summary
2 Introduction
Membrane Receptor Pathways
Mitogen-Activated Protein Kinase Pathways
G-Protein Coupled Receptors
PI3K/Akt Signalling
Jak/STAT Signalling
NF-kB Signalling
Insulin Signalling
B Cells and T Cells
Nuclear Receptors
Nuclear Receptor Structure
Nuclear Receptors as Pharmaceutical Targets
3 Cancer
Market for Novel Therapies
Cell Cycle Control
Manipulation of the Cell Cycle to Enhance the Therapeutic Window
Cyclin-Dependent Kinase Modulators in Clinical Development
Flavopiridol
UCN-01
Molecular Targets for Cancer Drug Development
Bcl-2
Bcr/Abl
Cyclo-oxygenase
The ErbB Family
Farnesyl Transferase
FLT3
Heat Shock Protein 90
Kit
Mammalian Target of Rapamycin (mTOR)
Mitogen Activated ERK Kinase (MEK)
Proteasome
Protein Kinase C
Raf-1 Kinase
Src Protein Kinase
Vascular Endothelial Growth Factor
Signal Transduction Modulators in Clinical Development for Cancer
Critical Aspects of Clinical Trial Design
17-AAG
Affinitak™
AP23573
AP23464
ARRY-142886
AZD3409
BAY 43-9006
Bevacizumab (Avastin™)
Bortezomib (Velcade™)
CCI-779
Celecoxib (Celebrex®)
CEP-701
CEP-7055
CI-1033
CI-1040
EKB-569
EMD72000
Erlotinib HCl
Gefitinib
GW572016
Imatinib mesylate
Lonafarnib (Sarasar™)
MLN518
Oblimersen (Genasense™)
OSI-461
Pertuzumab(Omnitarg™)
PKC412
RAD001
SU11248
Tipifarnib (Zarnestra®)
Trastuzumab (Herceptin®)
Vatalanib (PTK787)
VEGF Trap
ZD6474
Nuclear Receptors Targets for Cancer Therapy
Androgen Receptor
Estrogen Receptor (ER)
Progesterone Receptor (PR)
Nuclear Receptor Modulators as Cancer Therapeutics
Selective Estrogen Receptor Modulators (SERMS)
Aromatase Inhibitors
Fulvestrant (Faslodex®)
Signal Transduction Inhibitors and Endocrine Therapy
Prostate Cancer: Targeting the Androgen Receptor
Nuclear Receptors as Targets for Chemoprevention
Vitamin D Receptor (VDR)
Retinoic Acid Receptors (RAR and RXR)
4 Inflammatory/Autoimmune Disease
Molecular Targets for Anti-Inflammatory Drugs
Chemokines
Cyclooxygenase
Glucagon-like Peptide 2
Glucocorticoid Receptor (GR)
Intercellular Adhesion Molecule 1
Interleukin-1
Retinoid-Related Orphan Receptor a (RORa) and Inflammation
Tumor Necrosis Factor
Rheumatoid Arthritis
Signal Transduction Modulators in Development for Rheumatoid Arthritis
Inflammatory Bowel Disease
Signal Transduction Modulators in Clinical Development for Inflammatory Bowel Diseases
Multiple Sclerosis
Targeted Drug Candidates in Development for MS
5 Metabolic Syndrome
Molecular Targets for Drugs to Treat Metabolic Syndrome
ß3-Adrenoceptor
Glucagon-Like Peptide 1
Leptin
Peroxisome Proliferator Activated Receptor (PPAR)
Protein Kinase C-ß
Protein Tyrosine-Phosphatase 1B
Diabetes (Type 2)
Anti-Diabetic Drugs in Clinical Development
Obesity
Anti-Obesity Drugs in Clinical Development
6 Company Profiles
Abbott Laboratories
Overview
Financial Information
Products and Services (Pharmaceutical Products)
Key Development Products
Management
Amylin Pharmaceuticals
Overview
Financial Information
Key Development Products
Alliances
Management
Ariad Pharmaceuticals
Overview
Financial Information
Key Development Products
Management
Array BioPharma
Overview
Financial Information
Products and Services
Alliances
Management
AstraZeneca
Overview
Financial Information
Products and Services
Key Development Products
Management
Aventis
Overview
Financial Information
Products and Services
Key Development Products
Alliances
Management
Bayer
Overview
Financial Information
Products and Services (Bayer Health Care)
Alliances
Management
BioMS Medical
Overview
Financial Information
Key Development Products
Management
Bristol-Myers Squibb
Overview
Financial Information
Products and Services (Pharmaceutical Division)
Key Development Products
Alliances
Management
CellTech
Overview
Financial Information
Key Development Products
Management
Cephalon
Overview
Financial Information
Products and Services
Key Development Products
Management
ChemoCentryx
Overview
Key Development Products
Management
ConjuChem
Overview
Financial Information
Key Development Products
ManagementEli Lilly
Overview
Financial Information
Products and Services
Key Development Products
Alliances
Management
EMD Pharmaceuticals
Overview
Key Development Products
Management
Genentech
Overview
Financial Information
Products and Services
Key Development Products
Alliances
Management
Genta
Overview
Financial Information
Products and Services
Key Development Products
Management
GlaxoSmithKline
Overview
Financial Information
Products and Services
Key Development Products
Alliances
Management
Human Genome Sciences
Overview
Financial Information
Key Development Products
Alliances
Management
Ilex Oncology
Overview
Financial Information
Products and Services
Key Development Products
Management
Isis Pharmaceuticals
Overview
Financial Information
Products and Services
Key Development Products
Alliances
Management
Johnson and Johnson
Overview
Financial Information
Products and Services (Pharmaceuticals)
Management
Ligand Pharmaceuticals
Overview
Financial Information
Products and Services
Key Development Products
Alliances
Management
Metabolex
Overview
Key Development Products
Alliances
Management
Metabolic Pharmaceuticals
Overview
Financial Information
Key Development Products
Management
Millennium
Overview
Financial Information
Products and Services
Key Development Products
Alliances
Management
Nastech Pharmaceutical Company
Overview
Financial Information
Key Development Products
Management
Neurocrine Biosciences
Overview
Financial Information
Key Development Products
Alliances
Management
Novartis
Overview
Financial Information
Products and Services
Key Development Products
Management
Novo Nordisk
Overview
Financial Information
Products and Services
Key Development Products
Management
NPS Pharmaceuticals
Overview
Financial Information
Products and Services
Key Development Products
Alliances
Management
Onyx
Overview
Financial Information
Products and Services
Key Development Products
Alliances
Management
OSI Pharmaceuticals
Overview
Financial Information
Products and Services
Key Development Products
Management
Pfizer
Overview
Financial Information
Products and Services
Key Development Products
Management
Regeneron
Overview
Financial Information
Key Development Products
Alliances
Management
Sanofi-Synthelabo
Overview
Financial Information
Products and Services
Key Development Products
Management
Schering Plough
Overview
Financial Information
Products and Services
Key Development Products
Management
Tularik
Overview
Financial Information
Key Development Products
Alliances
Management
Wyeth
Overview
Financial Information
Key Development Products
Alliances
Management
7 Concluding Remarks
Promising Cancer Drug Candidates
Promising Drug Candidates for Inflammatory and Autoimmune Diseases
Promising Drug Candidates for Metabolic Syndrome
|
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/224766
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 11/10/2008 07:06:06 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Cell Signalling Pathways - Productive Sources of Pharmaceutical Targets
|
|
Web Address: |
http://www.researchandmarkets.com/reports/224766
|
|
Office Code: |
|
OCHKELLPTOX
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic
|
|
€5,297.00
|
|
Electronic
- Site License
|
|
€7,415.00
|
|
Electronic
- Enterprisewide
|
|
€7,945.00
|
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World
|
|
Page 2 of 2
Printed 11/10/2008 07:06:06
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder Name: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World
|
|
|
|
|
|
